BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 6, 2025
Home
»
Authors
»
Aaron Lorenzo
Articles by Aaron Lorenzo
Angiogenix Raises $12M In Series C For Acclaim Product
Dec. 19, 2002
By
Aaron Lorenzo
Targeted Genetics Continues Cutbacks To Conserve Cash
Dec. 18, 2002
By
Aaron Lorenzo
Versicor Starts Phase III Trials Of Dalbavancin For Infections
Dec. 18, 2002
By
Aaron Lorenzo
Targeted Genetics Continues Cutbacks To Conserve Cash
Dec. 18, 2002
By
Aaron Lorenzo
Versicor Starts Phase III Trials Of Dalbavancin For Infections
Dec. 18, 2002
By
Aaron Lorenzo
AdipoGenix Lands Deal With J&J For Program In Obesity
Dec. 17, 2002
By
Aaron Lorenzo
AdipoGenix Lands Deal With J&J For Program In Obesity
Dec. 17, 2002
By
Aaron Lorenzo
Neurochem Raises C$8M, Could Realize More With Warrants Sale
Dec. 13, 2002
By
Aaron Lorenzo
Neurochem Raises C$8M, Could Realize More With Warrants Sale
Dec. 13, 2002
By
Aaron Lorenzo
Northwest, Medarex, Millennium Dealing Cancer Products, IP
Dec. 12, 2002
By
Aaron Lorenzo
Previous
1
2
…
212
213
214
215
216
217
218
219
220
…
237
238
Next
